Trehalose - JunaxoAlternative Names: JNX-3001
Latest Information Update: 29 Feb 2016
At a glance
- Originator Junaxo
- Class Disaccharides; Glucans; Small molecules
- Mechanism of Action Protein aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease